Duration of tamoxifen effect on lipidemic profile of postmenopausal breast cancer patients following deprivation of treatment

Oncology

Volumn 70, Issue 4, 2006, Pages 301-305

  Markopoulos, Christos ^a,b   Chrissochou, M ^a   Antonopoulou, Z ^a   Xepapadakis, G ^a   Papadiamantis, J ^a   Tzoracoleftherakis, E ^a   Gogas, H ^a  

^a Hellenic Society of Breast Surgeons   (Greece)

^b NONE   (Greece)

Author keywords

Aromatase inhibitors; Cholesterol; High density lipoprotein; Low density lipoprotein; Tamoxifen; Triglycerides

Indexed keywords

EXEMESTANE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE MARKER; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LIPID ANALYSIS; LIPID METABOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LIPID METABOLISM; LIPIDS; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 33750539317     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096251     Document Type: Article

References (21)

1. Osborne CK: Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-1618.
2. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998;351:1451-1467.
3. Riggs LR, Hartmann LC: Selective estrogen receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618-629.
4. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Br Med J 1991;303:435-437.
5. Rutqvist LE, Mattson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-1406.
6. Fisher B, Costantino JP, Wickerham L, Redmont CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998;90:1371-1388.
7. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776-782.
8. Love RR, Wiebe DA, Feyzi JM, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal woman after 5 years of treatment. J Natl Cancer Inst 1994;86:1534-1539.
9. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I: Antiaetherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in post-menopausal woman with node-positive breast cancer. J Clin Oncol 1996;14:429-433.
10. Joensuu H, Holli K, Oksanen H, Valavaara R: Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. Breast Cancer Res Treat 2000;63:225-234.
11. Elisaf M, Bairaktari E, Nicolaides C, et al: The beneficial effect of tamoxifen on serum lipoprotein-A levels: an additional anti-atherogenic property. Anticancer Res 1996;16: 2725-2728.
12. Laird NM, Ware JH: Random effect models for longitudinal data. Biometrics 1982;38: 963-974.
13. Samsioe G: Cardioprotection by estrogens: mechanisms of action - the lipids. Int J Fertil Menopausal Stud 1994;39(suppl 1):43-49.
14. Langan-Fahey SM, Tormey DC, Jordan VC: Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer. Eur J Cancer 1990;26:882-883.
15. Love RR, Newcomb PA, Wiebe DA, Surawicz TS, Jordan VC, Carbone PP, et al: Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:13227-13232.
16. Muthusamy T, Kalyanam K, Rengasamy G, Panchanatham S: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 1994;73:659-663.
17. Umland EM, Rinaldi C, Parks SM, Boyce EG: The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynaecologic cancers. Ann Pharmacother 1999;33:1315-1328.
18. Goss PE, Ingle JN, Martino S, et al: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer. N Engl J Med 2003;349:1793-1802.
19. Wasan KM, Goss PE, Pritchard PH, et al: The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen. Ann Oncol 2005;16:707-715.
20. The BIG 1-98 Collaborative Group: A comparison of letrozol and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-2757.
21. Markopoulos C, Chrissochou M, Michailidou A, et al: Effect of exemestane on the lipidemic profile of post menopausal operable breast cancer patients following 5-7 years of adjuvant tamoxifen: preliminary results of the ATENA substudy. Anticancer Drugs 2005;16:879-883.